Nautilus Biotechnology (NAUT) Accumulated Expenses (2020 - 2026)

Nautilus Biotechnology has disclosed Accumulated Expenses across 7 years of filings, most recently posting $3.3 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $3.3 million, up 7.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.3 million (up 7.55% YoY), and the FY2025 annual result was $3.2 million, up 24.69% from the prior year.
• Accumulated Expenses came in at $3.3 million for Q1 2026 at Nautilus Biotechnology, up from $3.2 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $4.3 million in Q3 2023 to a low of $2.5 million in Q4 2024.
• The 5-year median for Accumulated Expenses is $3.4 million (2023), against an average of $3.4 million.
• Across the five-year window, Accumulated Expenses jumped 136.17% in 2022 and plunged 35.41% in 2024, its largest moves.
• Nautilus Biotechnology's Accumulated Expenses stood at $3.5 million in 2022, then rose by 11.82% to $3.9 million in 2023, then slumped by 35.41% to $2.5 million in 2024, then climbed by 24.69% to $3.2 million in 2025, then advanced by 4.03% to $3.3 million in 2026.
• The last three Accumulated Expenses figures came in at $3.3 million (Q1 2026), $3.2 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.